Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores.

Moore RA, Moore OA, Derry S, McQuay HJ.

Arthritis Res Ther. 2008;10(2):R39. doi: 10.1186/ar2394. Epub 2008 Apr 2.

2.

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.

Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H.

Ann Rheum Dis. 2010 Feb;69(2):374-9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.

3.

Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.

Peloso PM, Gammaitoni A, Smugar SS, Wang H, Moore AR.

BMC Musculoskelet Disord. 2011 Jul 18;12:165. doi: 10.1186/1471-2474-12-165.

4.

A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.

Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS.

Osteoarthritis Cartilage. 2007 Dec;15(12):1348-56. Epub 2007 Jul 16.

5.

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ; Protocol 007 Study Group.

Rheumatology (Oxford). 2002 Sep;41(9):1052-61. Erratum in: Rheumatology (Oxford). 2003 Jun;42(6):814.

6.

Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.

Bingham CO 3rd, Bird SR, Smugar SS, Xu X, Tershakovec AM.

Osteoarthritis Cartilage. 2008 Nov;16(11):1289-93. doi: 10.1016/j.joca.2008.04.009. Epub 2008 Jun 2.

7.

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].

Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, Reicin AS.

BMC Musculoskelet Disord. 2005 Dec 1;6:58.

8.

Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.

Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, Geba GP; Etoricoxib Protocol 042 Study Group.

J Pain. 2003 Aug;4(6):307-15.

PMID:
14622687
10.

Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.

van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, James M, Markind JE, Reicin AS, Melian A, Dougados M.

Arthritis Rheum. 2005 Apr;52(4):1205-15.

11.

Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study.

Viscusi ER, Frenkl TL, Hartrick CT, Rawal N, Kehlet H, Papanicolaou D, Gammaitoni A, Ko AT, Morgan LM, Mehta A, Curtis SP, Peloso PM.

Curr Med Res Opin. 2012 Aug;28(8):1323-35. doi: 10.1185/03007995.2012.707121. Epub 2012 Jul 16.

PMID:
22738802
12.
14.

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.

Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS.

Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.

15.

Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.

Moore RA, Derry S, McQuay HJ.

Arthritis Res Ther. 2008;10(3):R53. doi: 10.1186/ar2422. Epub 2008 May 8.

16.

Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial.

Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R, O'Brien K, Mucciola L, Skalky CS, Petruschke RA, Bohidar NR, Geba GP.

Scand J Rheumatol. 2004;33(4):257-66.

PMID:
15370723
17.

Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.

Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE 2nd, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O.

Clin Ther. 2006 Sep;28(9):1279-95.

PMID:
17062301
18.
19.

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.

Rheumatology (Oxford). 2007 Mar;46(3):496-507. Epub 2006 Aug 27.

20.

Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.

Greenwald M, Peloso PM, Mandel D, Soto O, Mehta A, Frontera N, Boice JA, Zhan XJ, Curtis SP.

Curr Med Res Opin. 2011 Oct;27(10):2033-42. doi: 10.1185/03007995.2011.614935. Epub 2011 Sep 12.

PMID:
21905970
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk